中国实用口腔科杂志

中国实用口腔科杂志 ›› 2023, Vol. 16 ›› Issue (6): 752-756.DOI: 10.19538/j.kq.2023.06.019

• 综述 • 上一篇    下一篇

富血小板纤维蛋白在药物相关性颌骨坏死预防和治疗中的研究进展

曾叶渐，王    军，邹海啸   

  1. 南昌大学第二附属医院口腔颌面外科，江西  南昌 330000
  • 出版日期:2023-11-30 发布日期:2023-12-20

  • Online:2023-11-30 Published:2023-12-20

摘要： 药物相关性颌骨坏死（medication-related osteonecrosis of the jaw，MRONJ）是一种严重的并发症，发生于使用双膦酸盐类等药物的患者身上，主要表现为颌骨坏死。目前，MRONJ的治疗方法尚存在争议，缺乏明确的治疗金标准。富血小板纤维蛋白（platelet-rich fibrin，PRF）是第二代富血小板血液浓缩物，其制备相较于第一代富血小板血浆（platelet-rich plasma，PRP）更为简便，且具有较低的免疫原性危险和感染风险。然而，PRF在MRONJ的手术辅助治疗方面是否能起到促进创口愈合和软硬组织再生的作用尚不明确。文章就近年来关于PRF在MRONJ中应用的研究进展做一综述，旨在探讨PRF在预防和治疗MRONJ中的效果。

关键词: 药物相关性颌骨坏死, 双膦酸盐, 富血小板纤维蛋白

Abstract: Medication-related osteonecrosis of the jaw（MRONJ）is a severe complication that occurs in patients taking bisphosphonates and other related drugs，primarily manifested as jawbone necrosis. Currently，there is no widely accepted treatment for MRONJ，and the optimal approach remains controversial. Platelet-rich fibrin（PRF）is a second-generation platelet concentrate that is easier to prepare compared to its first-generation counterpart，platelet-rich plasma（PRP）. Additionally，PRF presents lower risks of immunogenicity and infection. However，the effectiveness of PRF as an adjunctive treatment for MRONJ in promoting healing and regeneration of soft and hard tissues is still not clear. This article aims to provide a comprehensive review of recent research progress on the application of PRF in MRONJ，hoping to explore its potential efficacy in both the prevention and treatment of MRONJ.

Key words: medication-related osteonecrosis of the jaw, bisphosphonates, platelet-rich fibrin